OncoMatch/Clinical Trials/NCT06832865
ELISA in Relapsed/Refractory MM
Official title: A Phase 2 Study of Elranatamab in Combination With Isatuximab (ELISA) in Relapsed and Refractory Multiple Myeloma
Is NCT06832865 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including elranatamab and Isatuximab SC for relapsed refractory multiple myeloma (rrmm).
Treatment: elranatamab · Isatuximab SC · Isatuximab SC-OBDS — This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple myeloma (RRMM) who have received at least one prior line of therapy and who have had previous treatment with both immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI). The subcutaneous injection method of isatuximab administration, including the device used to administer isatuximab, is investigational.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunomodulatory drug
patients who have had previous treatment with both immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI)
Must have received: proteasome inhibitor
patients who have had previous treatment with both immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI)
Cannot have received: anti-BCMA bispecific T cell engager
Previous treatment with an anti-BCMA bispecific T cell engager
Lab requirements
Blood counts
ANC ≥ 1000/μL (no G-CSF within 7 days); Platelet count ≥ 50,000/µL (no platelet transfusion within 7 days); Hemoglobin ≥ 8 g/dL (RBC transfusions permitted)
Kidney function
Calculated creatinine clearance of ≥ 30 mL/min by Cockcroft-Gault equation
Liver function
Serum bilirubin < 2 mg/dL (Gilbert's syndrome <3 mg/dL and normal direct bilirubin); ALT/AST < 2.5 × ULN
Cardiac function
NYHA class 2B or better; no impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment
Participants must have adequate organ and marrow function as defined below: ... Patient has adequate hepatic function ... Calculated creatinine clearance ... NYHA class 2B or better ...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06832865 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-BCMA bispecific T cell engager disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages